SightfileU.S. market data from official filings

MYRIAD GENETICS INC (MYGN)

Name: MYRIAD GENETICS INC (MYGN) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0000899923 · EDGAR filings · Updated 2026-06-23

MYRIAD GENETICS INC (MYGN) has reported institutional ownership of 93.0%, with 202 institutional managers holding positions valued at $518.4M per the latest 13F reporting period.

Institutional ownership

93.0%

Institutional managers

202

Reported 13F value

$518.4M

Insider activity

62 trans.

$694.5K net buying

Latest updates

2026-06-23 — Insider transaction reported (Form 4)
2026-06-23 — Current report (8-K) filed
2026-06-12 — Insider transaction reported (Form 4)
2026-06-12 — Insider transaction reported (Form 4)
2026-06-09 — Insider transaction reported (Form 4)
2026-06-08 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, MYRIAD GENETICS INC has 202 institutional holders and institutional ownership of 93.0%.

Insider activity

Insiders reported 62 transactions (4 buys, 0 sells) across 20 reporting insiders, with a net reported value of $694.5K.

Related companies

OCULIS HOLDING AG (OCS) · KAMADA LTD (KMDA) · ZAI LAB LTD (ZLAB) · PRECIGEN (PGEN) · BRIDGEBIO ONCOLOGY THERAPEUTIC (BBOT) · COMPASS PATHWAYS ADR A FUNSPONSORED ADR 1 ADR REPS 1 ORD SHS (CMPS)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-06-23.